Skip to main content
Premium Trial:

Request an Annual Quote

University of Hawaii to Outfit New Facility With ABI Expression Analysis Platform

HONOLULU, Jan. 19 (GenomeWeb News) - A new research facility at the University of Hawaii's John A. Burns Medical School will outfit its labs with Applied Biosystems' Expression Analysis gene expression-analysis platform, GenomeWeb News has learned.


ABI "seemed interested in collaborating and working with us," Richard Lairton, an assistant professor of medicine at the school, told GenomeWeb News here last week. "We wanted a partnership and they seemed interested in collaborating in our research and supporting their platform with bioinformatics."


The EA platform will complement the school's ABI DNA-sequencing technology as well as the company's Taqman chemistries. The facility will open in September.


The facility will sit on a 10-acre lot on the Honoluluwaterfront. A 100,000-square-foot building will welcome students in the spring, and the research facilities will open in the late summer.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.